Cetera Investment Advisers Makes New Investment in Pulse Biosciences, Inc $PLSE

Cetera Investment Advisers purchased a new stake in shares of Pulse Biosciences, Inc (NASDAQ:PLSE) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 17,928 shares of the company’s stock, valued at approximately $387,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc grew its position in shares of Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after purchasing an additional 8,197 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Pulse Biosciences in the first quarter worth $323,000. Goldman Sachs Group Inc. raised its position in shares of Pulse Biosciences by 31.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 22,453 shares of the company’s stock worth $308,000 after buying an additional 5,322 shares in the last quarter. Norges Bank bought a new stake in Pulse Biosciences during the second quarter valued at $302,000. Finally, California State Teachers Retirement System boosted its stake in Pulse Biosciences by 23.2% during the fourth quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock valued at $291,000 after buying an additional 3,991 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Stock Performance

NASDAQ PLSE opened at $47.85 on Friday. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $48.84. The company has a fifty day moving average of $32.56 and a 200-day moving average of $25.67. The company has a market capitalization of $3.31 billion, a P/E ratio of -40.55 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. As a group, analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Canaccord Genuity Group boosted their target price on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC assumed coverage on Pulse Biosciences in a report on Monday. They issued a “buy” rating and a $58.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pulse Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.